RT Journal Article SR Electronic T1 Development and Potential Use of a Monoclonal Antibody to the Lipopolysaccharide of Pantoea agglomerans (IP-PA1) JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3701 OP 3706 VO 27 IS 6A A1 TANIGUCHI, YOSHIE A1 NISHIZAWA, TAKASHI A1 HONDA, TERUKO A1 YOSHIOKA, NORIKO A1 INAGAWA, HIROYUKI A1 KOHCHI, CHIE A1 SOMA, GEN-ICHIRO YR 2007 UL http://ar.iiarjournals.org/content/27/6A/3701.abstract AB Background: The lipopolysaccharide of Pantoea agglomerans (IP-PA1) has been shown to be effective and safe in the prevention of various diseases, such as bacterial or viral infection, lifestyle-related diseases, when administered transdermally or orally. To clarify the mechanisms of the preventive or therapeutic effect induced by IP-PA1, we tried to establish a monoclonal antibody to detect IP-PA1. The enzyme-linked immunosorbent assay (ELISA) was used to measure the amount of IP-PA1. Materials and Methods: Antibodies were raised by immunization using heat-killed Pantoea agglomerans and screening was conducted to isolate monoclonal antibodies specific to IP-PA1. Results: Six kinds of IP-PA1 specific monoclonal antibodies with different epitopes were established. An ELISA using the monoclonal antibodies was successfully established which could specifically detect IP-PA1. Conclusion: By use of this ELISA, the staple food content and pharmacodynamic analysis of IP-PA1 could be conveniently estimated. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved